Cytogenetics and molecular genetics of myelodysplastic neoplasms
Copyright © 2023 Elsevier Ltd. All rights reserved..
According to the 2022 World Health Organization (WHO) Classification (5th edition), the term myelodysplastic neoplasms (abbreviated MDS) has been introduced to replace myelodysplastic syndromes. MDS are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more of lineages, ineffective hematopoiesis, and an increased risk of progression to bone marrow failure or to acute myeloid leukemia (AML). Current NCCN guidelines and recent review articles have provided in depth discussion on the clinical diagnosis and management of MDS. This review will focus on discussion of the WHO and International Consensus Classification (ICC) updates on the role of cytogenetics and molecular genetics in the diagnosis and risk stratification of MDS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Best practice & research. Clinical haematology - 36(2023), 4 vom: 11. Dez., Seite 101512 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ning, Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 28.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.beha.2023.101512 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36583176X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36583176X | ||
| 003 | DE-627 | ||
| 005 | 20231229124224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.beha.2023.101512 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM36583176X | ||
| 035 | |a (NLM)38092472 | ||
| 035 | |a (PII)S1521-6926(23)00073-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ning, Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytogenetics and molecular genetics of myelodysplastic neoplasms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 28.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a According to the 2022 World Health Organization (WHO) Classification (5th edition), the term myelodysplastic neoplasms (abbreviated MDS) has been introduced to replace myelodysplastic syndromes. MDS are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more of lineages, ineffective hematopoiesis, and an increased risk of progression to bone marrow failure or to acute myeloid leukemia (AML). Current NCCN guidelines and recent review articles have provided in depth discussion on the clinical diagnosis and management of MDS. This review will focus on discussion of the WHO and International Consensus Classification (ICC) updates on the role of cytogenetics and molecular genetics in the diagnosis and risk stratification of MDS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a MDS diagnosis | |
| 650 | 4 | |a MDS genetics | |
| 650 | 4 | |a MDS management | |
| 650 | 4 | |a MDS prognosis | |
| 700 | 1 | |a Zhang, Yanming |e verfasserin |4 aut | |
| 700 | 1 | |a Kallen, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Emadi, Ashkan |e verfasserin |4 aut | |
| 700 | 1 | |a Baer, Maria R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Best practice & research. Clinical haematology |d 2001 |g 36(2023), 4 vom: 11. Dez., Seite 101512 |w (DE-627)NLM112621287 |x 1532-1924 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:4 |g day:11 |g month:12 |g pages:101512 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.beha.2023.101512 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 4 |b 11 |c 12 |h 101512 | ||